Treatment Services

Treatment Services Fucaso

Patient Story

Patient Support

CAR-T Therapy Center Multiple Myeloma Specialist Team Insurance Introduction

About Car-T Therapy

What is Car-T? Who is Car-T for? For Caregivers Car-T therapy vs. conventional therapy Find CAR T Medical Center Cart-T Drugs for Multiple Myeloma Car-T Treatment Process Guide CAR-T Post-Treatment Care and Rehabilitation Guide

About Multiple Myeloma

What can I do after my myeloma is confirmed? Multiple Myeloma Treatment Options What is Mutiple Myeloma?

Counseling for Help

Resources

Blogs Downloads

For Doctors
Equecabtagne autoleucel （FUCASO）Clinical Facts and Clincal Handling Guidance
DOWNLOAD
For Patients
Your guide to Equecabtagene Autoleucel（ FUCASO ）
For the treatment of adult patients with relapsed or refractory multiple myeloma.
DOWNLOAD
Other Resources
Blogs About Multiple Myeloma About Car-T Therapy Patients Story Treatment Centre Enquiry CAR-T International Medical Services
Complete our quick survey to unlock your free download of resources.
Full Name
Country
City
Hospital/Research Institution
Contact Email
Specialty Area
Hematology (Blood disorders)
Immunology/Immunotherapy
Medical Oncology (Chemotherapy and pharmacologic treatments)
Radiation Oncology (Radiation therapy)
Bone Marrow Transplantation
Pain Management
Orthopedics
Mental Health Services
Rehabilitation Medicine
Clinical Pharmacology
Nursing Services
Other
* Please select your current position within your organization
Administrative Level
Staff Physician/Nurse
Lead Physician/Nurse
Department Head
Director of Oncology Services
Medical Director
Other
*Please select your primary department
*Required
Upload case photos for expert advice

Maximum 6 images，3Mb each picture limited
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found
fucaso fucaso Learn More

We use cookies to ensure that you get the best experience on our website. Clicking "Accept Cookies" means you agree with our Privacy Policy.

Accept Cookies